AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
30 Winter Street
Boston
Massachusetts
02108
United States
457 articles about AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
-
AVEO Pharmaceuticals, Inc. Receives $5 Million Milestone Payment from Biogen Idec, Inc. (Massachusetts) Under Licensing Agreement for ErbB3 Antibody Program
4/14/2010
-
Data from AVEO Pharmaceuticals, Inc.'s Translational Research Platform and Novel Antibody Pipeline to be Presented at American Association for Cancer Research 101st Annual Meeting 2010
4/13/2010
-
AVEO Pharmaceuticals, Inc. Announces Exercise of Over-Allotment Option for Recent Initial Public Offering
4/1/2010
-
AVEO Pharmaceuticals, Inc. Completes Initial Public Offering
3/18/2010
-
AVEO Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
3/12/2010
-
AVEO Pharmaceuticals, Inc. Sets IPO Terms
2/24/2010
-
AVEO Pharmaceuticals, Inc. Files Registration Statement for Initial Public Offering
12/17/2009
-
AVEO Pharmaceuticals, Inc.'s Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting
11/20/2009
-
AVEO Pharmaceuticals, Inc. to Present at the JMP Securities Healthcare Focus Conference
10/1/2009
-
AVEO Pharmaceuticals, Inc. Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors
9/16/2009
-
AVEO Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
9/4/2009
-
AVEO Pharmaceuticals, Inc. to Present at the Canaccord Adams 29th Annual Global Growth Conference
8/4/2009
-
AVEO Pharmaceuticals, Inc.'s Tivozanib Demonstrates Anti-Tumor Activity in Engineered Lung Tumors Exhibiting Treatment Resistant Mutations
7/31/2009
-
AVEO Pharmaceuticals, Inc. to Present at IBC Life Sciences' New Frontiers in Cancer Drug Development Conference
7/30/2009
-
AVEO Pharmaceuticals, Inc. Nabs $20M From Extended Deal with OSI Pharmaceuticals, Inc.
7/21/2009
-
AVEO Pharmaceuticals, Inc. Granted Patent for Protection of its Directed Complementation Technology
7/8/2009
-
AVEO Pharmaceuticals, Inc. Granted Patent for Predictive Biomarker Used to Identify Human Tumors Likely to Respond to Notch Pathway Inhibition
6/17/2009
-
AVEO Pharmaceuticals, Inc. to Present at the 8th Annual Needham & Company Life Sciences Conference
6/5/2009
-
AVEO Pharmaceuticals, Inc.: AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer; Phase 2 Data Presented at American Society of Clinical Oncology
5/29/2009
-
AVEO Pharmaceuticals, Inc. to Present at Several Key Upcoming Medical and Industry Conferences
5/18/2009